NASDAQ$BVS
Bioventus Inc - A · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported strong first quarter with revenue growth and increased profitability, driven by Pain Treatments and Surgical Solutions, and raised full-year 2024 financial guidance reflecting enhanced revenue growth and strong execution of strategic priorities.
Bioventus reported a strong start to the year with an 8.7% increase in worldwide revenue, totaling $129.5 million, and a net loss from continuing operations of $6.0 million, which is an improvement compared to the prior-year period. The company's adjusted EBITDA from continuing operations increased by 33.5% to $22.6 million. Based on this momentum, Bioventus raised its full-year 2024 financial guidance.
- Worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period.
- On an organic basis, revenue increased 15.3%, driven by growth in Pain Treatments and Surgical Solutions.
- Net loss from continuing operations was $6.0 million, compared to a net loss of $100.0 million in the prior-year period.
- Adjusted EBITDA from continuing operations totaled $22.6 million, advancing 33.5% compared to the prior year.
Headline financials
Revenue & EPS history
Bioventus · Revenue · Quarterly
$129M
Forward guidance
Bioventus is raising financial guidance for full-year 2024.
Tailwinds
- Net sales of $535 million to $550 million
- Adjusted EBITDA of $94 million to $99 million
- Non-GAAP EPS of $0.25 to $0.33
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+2.1%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+13.1%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+26.0%
Q1 2024
Best reaction
-39.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.2% | -4.6% | -15.4% | |
| Q4 2025 | +7.4% | +4.6% | +5.9% | |
| Q3 2025 | +15.1% | +13.6% | +16.2% | |
| Q1 2025 | -12.0% | -5.0% | -7.4% | |
| Q4 2024 | +23.3% | +9.7% | -13.6% | |
| Q3 2024 | -17.7% | -13.8% | -15.1% | |
| Q2 2024 | +19.2% | +21.2% | +54.3% | |
| Q1 2024 | +26.0% | +35.0% | +70.0% | |
| Q4 2023 | -0.4% | +2.6% | -9.4% | |
| Q3 2023 | +6.0% | -2.1% | +42.1% | |
| Q2 2023 | +20.3% | +32.9% | -2.6% | |
| Q1 2023 | +6.5% | +58.5% | +195.9% | |
| Q4 2022 | -6.6% | +2.5% | -16.5% | |
| Q3 2022 | -39.9% | -42.7% | -18.9% | |
| Q2 2022 | +4.8% | +3.9% | -6.4% | |
| Q1 2022 | -9.1% | +4.5% | +12.5% | |
| Q4 2021 | +0.8% | -3.0% | -4.0% | |
| Q3 2021 | -0.5% | -4.5% | -18.7% | |
| Q2 2021 | +1.7% | +0.3% | -0.7% | |
| Q1 2021 | +1.0% | +3.3% | +17.0% | |
| Q4 2020 | -4.8% | -0.4% | -9.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro